MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

2.320 -0.030 (-1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 486,571
Open 2.350
Bid (Size) 2.310 (1)
Ask (Size) 2.420 (30)
Prev. Close 2.350
Today's Range 2.300 - 2.410
52wk Range 2.100 - 14.22
Shares Outstanding 40,243,745
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024
VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire

Performance

YTD
-72.05%
-72.05%
1 Month
-31.16%
-31.16%
3 Month
-80.70%
-80.70%
6 Month
-80.44%
-80.44%
1 Year
-75.66%
-75.66%

More News

Read More
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
From Verastem Oncology
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Verastem, Helios, and LegalZoom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
From Verastem Oncology
Via Business Wire
VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
From Kirby McInerney LLP
Via Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Rises 1%; Verastem Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
Via Benzinga
Is the Stock Market Open on Memorial Day 2024?
Via InvestorPlace
7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split
Via InvestorPlace
NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story